Radical cell therapy tested for lupus patients out of options
NCT ID NCT07266337
Summary
This early-stage study is testing a new type of treatment called CD19/BCMA CAR-T cell therapy for adults with severe systemic lupus erythematosus (lupus) that hasn't responded to standard treatments. The main goals are to check the treatment's safety, find the best dose, and see if it can reduce lupus disease activity and allow patients to stop other medications. Participants will receive a one-time infusion of the modified cells and be closely monitored for safety and effectiveness over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The General Hospital of Western Theater Command
Chengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.